Selecting the most appropriate model system is crucial to accurately recapitulate specific aspects of pathology. Different model systems have their advantages and limitations, and the choice depends on various factors, such as the nature of the pathology and the research goals. In response to the notable attrition rates in current drug development, there has been a shift in biomedical research towards human-based disease models, as well as complex model systems such as 3D and organotypic culture systems. While human-based preclinical models, and particularly iPSC-derived models, hold great promise to boost the success rate of drug development, and might even render animal models superfluous in the future, a deeper understanding of their physiology, epigenetic and gene expression profile will need to be achieved before they can be exclusively relied upon.

Concept Life Sciences offers a wide array of human and murine disease models covering various physiological and pathological conditions including those relating to neurodegeneration, immuno-oncology, inflammation and autoimmunity, and Fibrosis. Our assays suit diverse projects and can be tailored by our skilled and knowledgeable scientists based on your individual requirements.  

Our platform offers: 

• Assay Complexity: Models range from simple monoculture assays to more intricate versions involving two or more cell types.  
• Cell Diversity: Utilizes cell lines, primary cells, iPSC-derived cells, or combinations thereof within the assays.  
• Culture System Variability: Assays are conducted in both 2D and 3D culture systems, expanding the scope and depth of modelling capabilities.

‍

‍

Primary Cells Expertise

A drug candidate's entry into clinical trials heavily relies on efficacy and safety data derived from animal models. However, animal models frequently fail to effectively screen out harmful or ineffective drugs and can also exclude potentially effective drug candidates from entering clinical trials. 

Therefore, human-based models serve as indispensable tools throughout the drug development journey for the following reasons:

Target or Lead Molecule Identification: Human-based models are crucial for high-throughput screens, aiding in the identification of target or lead molecules ensuring clinical relevance.

Preclinical Efficacy and Safety Testing: These models play a pivotal role in conducting preclinical efficacy and safety tests, providing vital insights before clinical trials.

Integration into Clinical Trials: They form an integral part of clinical trials, contributing to decision-making processes, ensuring a more informed and effective implementation.

Enhanced Therapeutic Approaches: These models aid in the development of strategies that elevate the efficacy of treatments for various diseases.

‍